Recent News

• 09.17.2025 - Cingulate Secures Exclusive Manufacturing Partnership with Bend Bio Sciences to Support Future Commercialization of Next Generation ADHD Treatment
• 08.19.2025 - Cingulate Inc. Reports Second Quarter 2025 Financial Results and Provides Recent Highlights
• 08.15.2025 - Cingulate Provides Management Team Update
• 08.06.2025 - Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301
• 07.29.2025 - Cingulate Receives $4.3M Waiver from FDA Ahead of Imminent Filing for Marketing Approval of Lead ADHD Asset CTx-1301

Recent Filings

• 09.05.2025 - 8-K Current report
• 08.28.2025 - 8-K Current report
• 08.19.2025 - EX-99.1 EX-99.1
• 08.19.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.19.2025 - 8-K Current report
• 08.15.2025 - 8-K Current report
• 08.15.2025 - NT 10-Q Notification of inability to timely file Form 10-Q or 10-QSB
• 08.15.2025 - DEF 14A Other definitive proxy statements
• 08.08.2025 - 8-K Current report
• 08.06.2025 - 8-K Current report